Application of an amyloid beta oligomer standard in the sFIDA assay

Frontiers in Neuroscience

Luriano ePeters¹  Yvonne eHerrmann¹  Christina eLinnartz¹  Maren eHülsemann¹  Johannes eWillbold¹  Katja eKühbach¹  Kateryna eKravchenko¹  Kun eWang¹  Andreas eKulawik¹  Dieter eWillbold²  Oliver eBannach² 

[1] Forschungszentrum Jülich GmbH;Heinrich-Heine-Universität Düsseldorf;

关键词: Alzheimer’s disease;    early diagnosis;    Amyloid-β peptide;    Diagnostic biomarker;    sFIDA;    surface-based fluorescence intensity distribution analysis;   

DOI  :  10.3389/fnins.2016.00008

来源: DOAJ

【 摘 要 】

Still, there is need for significant improvements in reliable and accurate diagnosis for Alzheimer’s disease (AD) at early stages. It is widely accepted that changes in the concentration and conformation of amyloid-β (Aβ) appear several years before the onset of first symptoms of cognitive impairment in AD patients. Because Aβ oligomers are possibly the major toxic species in AD, they are a promising biomarker candidate for the early diagnosis of the disease. To date, a variety of oligomer-specific assays have been developed, many of them ELISAs. Here, we demonstrate the sFIDA assay, a technology highly specific for Aβ oligomers developed towards single particle sensitivity. By spiking stabilized Aβ oligomers to buffer and to body fluids from control donors, we show that the sFIDA readout correlates with the applied concentration of stabilized oligomers diluted in buffer, cerebrospinal fluid (CSF), and blood plasma over several orders of magnitude. The lower limit of detection was calculated to be 22 fM of stabilized oligomers diluted in PBS, 18 fM in CSF and 14 fM in blood plasma.

【 授权许可】

Unknown